More on SHPGY
Data
Financials
News
|
Shire pic (NQ:SHPGY)
Delayed: 85.67
-0.17 (0.2%)
|
Trade Now! |
|
||||
|---|---|---|---|---|---|---|
| Previous Close | $85.84 | 52 Week High | $108.79 | |||
| Open | $86.18 | 52 Week Low | $80.09 | |||
| Day High | $86.44 | P/E | N/A | |||
| Day Low | $85.57 | EPS | $0.00 | |||
| Volume | 196,308 | |||||
- Impax (IPXL), Shire (SHPGY) Settle Litigation Tied to Generic Adderall XR
- Barclays Upgrades Shire plc (SHPGY) to Overweight
- Shire plc (SHPGY) Reports Statistically Significant Data for VPRIV in Type 1 Gaucher Disease
- Notable Analyst Rating Changes 06/26: (JPM) (SHPGY) (PBI) Upgraded; (CTSH) (MS) (DOW) Downgraded
- Societe Generale Upgrades Shire plc (SHPGY) to Buy
- Morning Movers 06/25: (JAX) (LEE) (MDGN) Higher; (VTUS) (GEOY) (MNTA) (KEX) Lower
- Canaccord Genuity on Life Sciences: Generic Adderall XR Approval Offers Several Cross-stock Implications
- Nomura Securities Maintains a 'Buy' on Shire plc (SHPGY); FDA Approved Generic Version of Adderall-XR
- Actavis Adderall XR Approval Positive for Watson Pharm (WPI), Negative for Impax Lab (IPXL)
- Shire plc (SHPGY) Gets FDA Response for All Adderall XR ANDAs
Entities mentioned with SHPGY
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- UBS | View Related Stories »
- Citi | View Related Stories »
- Jefferies & Co | View Related Stories »
- Bank of America | View Related Stories »
- Merrill Lynch | View Related Stories »
- Lehman Brothers | View Related Stories »
- Show More...
